Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Bayer Schering Pharma Ag

Alexander Kuhl

Peter Kolkhof

Ingo Flamme

Jens-Kerim Ergüden

Karl-Heinz Schlemmer

Rolf Grosser

Lars Bärfacker

Santiago Figueroa Perez

Dieter Lang

Joachim Schuhmacher

Kai Thede

Heike Heckroth

Hanno Wild

Gunter Karig

Heike Gielen-Haertwig

Felix Oehme

Joachim Hütter

Andreas Knorr

Klaus Münter

Andreas Ohm

Adrian Funke

Erich Brendel

Frank Bröcker

Dennis Kvesic

Thomas Volkmer

The present invention relates to a pharmaceutical dosage form comprising an active ingredient combination of nifedipine or nisoldipine and at least one angiotensin II antagonist and/or at least one diuretic, characterized in that nifedipine or nisoldipine is released in the body in a controlled (modified) manner and the angiotensin II antagonist and/or the diuretic is released rapidly (immediate release (IR)), and also to processes for their preparation, to their use as medicaments and to their use for the prophylaxis, secondary prophylaxis or treatment of disorders.

Pharmaceutical dosage form comprising nifedipine or nisoldipine and an angiotensin II antagonist and/or a diuretic

The present application relates to novel dipyridyl-dihydropyrazolones, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.

4-(pyridin-3-yl)-2(pyridin-2yl)-1,2-dihydro-3H-pyrazol-3-one derivatives as specific HIF-pyrolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases

The present application relates to novel aryl- or heteroaryl-substitued pyrido[2,3-d] pyrimidines of formula (I), pharmaceuitical compositions of the same, and a process for their preparation. Formula(I) is: wherein Ar is an aryl or heteroaryl substituent, and R, R, R, Ar, D, and E are as defined in the specification. Compounds and compositions of the present invention can be used in the treatment and/or prophylaxis of various disorders in humans and animals, including aldosteronism, high blood pressure, chronic heart failure, the sequelae of a myocardial infarction, cirrhosis of the liver, renal failure, and stroke.

Aryl-or heteroaryl-substituted pyrido[2,3-d] pyrimidines and pharmaceutical compositions of the same

Dipyridyl-dihydropyrazolones and their use

The present application relates to novel 4-chromenonyl-1,4-dihydropyridinecarbonitriles, processes for their preparation, pharmaceutical compositions containing them, and their use for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.

4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof

The present application relates to novel 4-chromenonyl-1,4-dihydropyridines, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.

4-Chromenonyl-1,4-dihydropyridines and their use

Growing community of inventors

Hagen, Germany

Alexander Kuhl